Basic research and clinical studies are underway to identify genetic polymorphisms that underlie drug effects. What obstacles must we overcome before we can use genetic analysis to predict the ability of patients to respond to certain treatments?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Long-term whole blood DNA preservation by cost-efficient cryosilicification
Nature Communications Open Access 21 October 2022
-
ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure
Cell Discovery Open Access 23 October 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001).
The International SNP Map Working Group. A map of human genome sequence variation containing 1.4 million single nucleotide polymorphisms Nature 409, 928–933 (2001).
Malmstron, K. et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, control trial. Ann. Intern. Med. 130, 487–495 (1999).
Drazen, J.M., Silverman, E.R. & Lee, T.H. Heterogeneity of therapeutic responses in asthma. Br. Med. Bull. (in the press).
Fullerton, S.A. et al. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am. J. Hum. Genet. 67, 881–900 (2000).
Drysdale C.M. et al. Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Nat. Acad. Sci. USA 97, 10483–10488 (2000).
Small, K., Forbes, S.L., Rahman, F.F., Bridges, K.M. & Liggett, S.B. A four amino acid deletion polymorphism in the third intracellular loop of the human α2c-adrenergic receptor confers impaired coupling to multiple effectors. J. Biol. Chem. 275, 23059–23064 (2000).
Judson, R., Stephens, J.C. & Windemuth, A. The predictive power of haplotypes in clinical response. Pharmacogenomics 1, 2–23 (2000).
Ulbrecht, M. et al.Association of β(2)-adrenoreceptor variants with bronchial hyperresponsiveness. Am. J. Respir. Crit. Care. Med. 161, 469–474 (2000).
Drazen, J.M. et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168–170 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liggett, S. Pharmacogenetic applications of the Human Genome project. Nat Med 7, 281–283 (2001). https://doi.org/10.1038/85411
Issue Date:
DOI: https://doi.org/10.1038/85411
This article is cited by
-
Long-term whole blood DNA preservation by cost-efficient cryosilicification
Nature Communications (2022)
-
ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure
Cell Discovery (2018)
-
A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure
Nature Medicine (2008)
-
Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line
Journal of Gastroenterology (2007)
-
Current directions in chemotherapy for colorectal cancer
Journal of Gastroenterology (2006)